{"id":"https://openalex.org/W4239282176","doi":"https://doi.org/10.2174/1381612811306050907","title":"The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors","display_name":"The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors","publication_year":2012,"publication_date":"2012-12-01","ids":{"openalex":"https://openalex.org/W4239282176","doi":"https://doi.org/10.2174/1381612811306050907"},"language":"en","primary_location":{"id":"doi:10.2174/1381612811306050907","doi":"https://doi.org/10.2174/1381612811306050907","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1381612811306050907","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033135247","display_name":"An Wouters","orcid":"https://orcid.org/0000-0001-7771-1239","observed_orcids":["https://orcid.org/0000-0001-7771-1239"]},"institutions":[{"id":"https://openalex.org/I149213910","display_name":"University of Antwerp","ror":"https://ror.org/008x57b05","country_code":"BE","type":"education","lineage":["https://openalex.org/I149213910"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"An Wouters","raw_affiliation_strings":["University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.,Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.,Belgium","institution_ids":["https://openalex.org/I149213910"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000451772","display_name":"Carolien Boeckx","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolien Boeckx","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007067879","display_name":"Jan Baptist Vermorken","orcid":"https://orcid.org/0000-0001-8515-7848","observed_orcids":["https://orcid.org/0000-0001-8515-7848"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jan B. Vermorken","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109001597","display_name":"Dani\u00eblle Van den Weyngaert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle Van den Weyngaert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024390084","display_name":"Marc Peeters","orcid":"https://orcid.org/0000-0003-4969-2303","observed_orcids":["https://orcid.org/0000-0003-4969-2303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marc Peeters","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5007235093","display_name":"Filip Lardon","orcid":"https://orcid.org/0000-0001-7174-4144","observed_orcids":["https://orcid.org/0000-0001-7174-4144"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Filip Lardon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5033135247"],"corresponding_institution_ids":["https://openalex.org/I149213910"],"apc_list":null,"apc_paid":null,"fwci":0.1015,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.47257406,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"19","issue":"5","first_page":"907","last_page":"917"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.008999999612569809,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.9800000190734863},{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.9589999914169312},{"id":"https://openalex.org/keywords/hypoxia-inducible-factor-1alpha","display_name":"hypoxia-inducible factor-1\u03b1","score":0.8930000066757202},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.7210000157356262},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.8679999709129333},{"id":"https://openalex.org/keywords/panitumumab","display_name":"panitumumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.796999990940094},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.7870000004768372},{"id":"https://openalex.org/keywords/vascular-normalization","display_name":"vascular normalization","score":0.9070000052452087},{"id":"https://openalex.org/keywords/combined-radiotherapy","display_name":"combined radiotherapy","score":0.5910000205039978},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.875},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.8899999856948853},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7979999780654907}],"concepts":[{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6689429879188538},{"id":"https://openalex.org/C7836513","wikidata":"https://www.wikidata.org/wiki/Q1641506","display_name":"Hypoxia (environmental)","level":3,"score":0.6537631750106812},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5883505940437317},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.49347102642059326},{"id":"https://openalex.org/C2779081379","wikidata":"https://www.wikidata.org/wiki/Q7852677","display_name":"Tumor hypoxia","level":3,"score":0.4676489531993866},{"id":"https://openalex.org/C2776362946","wikidata":"https://www.wikidata.org/wiki/Q424374","display_name":"Epidermal growth factor","level":3,"score":0.45045995712280273},{"id":"https://openalex.org/C160450060","wikidata":"https://www.wikidata.org/wiki/Q104598479","display_name":"Hypoxia-inducible factors","level":3,"score":0.4471721947193146},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.43853721022605896},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.43320879340171814},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.4255187511444092},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4223729372024536},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.40996503829956055},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39100733399391174},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.38663387298583984},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3692591190338135},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22350963950157166},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.15262752771377563},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.12698325514793396},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07242819666862488},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C540031477","wikidata":"https://www.wikidata.org/wiki/Q629","display_name":"Oxygen","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2174/1381612811306050907","doi":"https://doi.org/10.2174/1381612811306050907","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1381612811306050907","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2081221684","https://openalex.org/W2022185594","https://openalex.org/W3092336032","https://openalex.org/W2108733591","https://openalex.org/W1505370951","https://openalex.org/W2765385720","https://openalex.org/W2096441944","https://openalex.org/W7100947079","https://openalex.org/W4368363931","https://openalex.org/W2972495314"],"abstract_inverted_index":{"Despite":[0],"their":[1,102,117],"individual":[2],"key":[3],"roles":[4],"in":[5,31,52,81,121,142,243],"promoting":[6],"cancer":[7,32,254],"progression":[8],"and":[9,33,39,48,71,105,135,148,166,230],"treatment":[10,256],"resistance,":[11,257],"our":[12],"knowledge":[13],"about":[14],"the":[15,21,24,61,86,108,161,196,210,227,234,239],"impact":[16],"of":[17,23,50,60,75,88,111,124,163,182,198,209,233],"tumor":[18,126,139],"hypoxia":[19,47],"on":[20],"activity":[22,110,120],"epidermal":[25],"growth":[26],"factor":[27,68],"receptor":[28],"(EGFR)":[29],"pathway":[30,242],"vice":[34],"versa":[35],"remains":[36,177],"limited.":[37],"Preclinical":[38],"clinical":[40,199],"studies":[41,221],"support":[42],"an":[43],"important":[44],"link":[45],"between":[46],"upregulation":[49],"EGFR":[51,64,129,172,240],"cancers":[53],"that":[54,77,195],"do":[55],"not":[56],"display":[57],"genetic":[58],"alterations":[59],"receptor.":[62],"Subsequent":[63],"signaling":[65,70,241],"stimulates":[66],"hypoxia-inducible":[67,248],"(HIF)":[69],"thus":[72,149,222],"augments":[73],"induction":[74],"proteins":[76],"promote":[78],"cellular":[79],"survival":[80],"a":[82],"hostile":[83],"microenvironment.":[84],"Considering":[85],"effects":[87],"EGFR-targeting":[89],"agents":[90],"under":[91],"reduced":[92],"oxygen":[93],"conditions,":[94],"it":[95],"is":[96,189],"now":[97],"accepted":[98],"that,":[99],"together":[100],"with":[101,128,158,171,185,213],"demonstrated":[103],"antiproliferative":[104],"proapoptotic":[106],"effects,":[107],"antiangiogenic":[109],"these":[112,183],"drugs":[113,184],"also":[114],"contributes":[115],"to":[116,132,160,178,201,225,238],"overall":[118],"antitumor":[119],"vivo.":[122],"Treatment":[123],"human":[125],"cells":[127],"inhibitors":[130],"leads":[131],"decreased":[133],"HIF-1\u03b1":[134,217],"VEGF":[136],"secretion":[137],"by":[138,207],"cells,":[140],"resulting":[141],"vascular":[143],"normalization,":[144],"improved":[145,150],"blood":[146],"flow":[147],"oxygenation.":[151],"These":[152],"findings":[153],"may":[154,204],"have":[155],"major":[156,175],"implications":[157,232],"respect":[159],"efficacy":[162],"both":[164],"radiotherapy":[165],"subsequent":[167],"chemotherapy":[168,188],"when":[169],"combined":[170],"inhibitors.":[173],"A":[174],"challenge":[176],"assess":[179],"which":[180],"sequence":[181],"radiation":[186],"or":[187,218],"optimal.":[190],"Moreover,":[191],"recent":[192],"data":[193],"suggest":[194],"lack":[197],"responses":[200],"EGFR-directed":[202],"therapy":[203,212],"be":[205],"circumvented":[206],"supplementation":[208],"anti-EGFR":[211],"additional":[214],"approaches":[215],"targeting":[216],"VEGF.":[219],"Further":[220],"are":[223],"warranted":[224],"define":[226],"precise":[228],"mechanistic":[229],"therapeutic":[231],"hypoxic":[235],"response":[236],"relative":[237],"cancer.":[244],"Keywords:":[245],"EGFR,":[246],"hypoxia,":[247],"factor,":[249],"cetuximab,":[250],"panitumumab,":[251],"gefitinib,":[252],"erlotinib,":[253],"progression,":[255],"microenvironment":[258]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2022-05-12T00:00:00"}